AstraZeneca Enhertu Breast Cancer Drug Is Recommended for EU Approval
27 Junio 2022 - 1:55AM
Noticias Dow Jones
By Jaime Llinares Taboada
AstraZeneca PLC said Monday that its Enhertu drug has been
recommended for approval in the European Union for patients with
breast cancer.
The pharmaceutical company said Enhertu has been recommended by
the EU's Committee for Medicinal Products for Human Use as a
monotherapy for the treatment of adults with unresectable or
metastatic HER2-positive breast cancer who have received one or
more prior anti-HER2-based regimens.
This decision was based on trial results showing that Enhertu
reduced the risk of disease progression or death by 72% compared
with the trastuzumab emtansine drug.
Enhertu has been jointly developed and commercialized by
AstraZeneca and Daiichi Sankyo Co.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
June 27, 2022 02:40 ET (06:40 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024